resmetirom
AssetSmall moleculeAlso MGL-3196, Rezdiffra, VIA-3196
Selective thyroid hormone receptor beta agonist that reduces hepatic fat accumulation
- Stage
- Approved
- Modality
- Small molecule
- Target
- Mitochondrial biogenesis (PGC-1α)
- Indications
- 12
- Trials
- 12
- Developers
- 2
Indications
12Fibrosis
Approvedaccessdata.fda.gov7 Oct 2026
Liver cirrhosis
Approvedema.europa.eu7 Oct 2026
Liver fibrosis
Approvedaccessdata.fda.gov7 Oct 2026
9 more
- Targets and what it contains3
- Owner and partners2
- Trials12
- Evidence for its targets4
- Competitors12
- Aging relevance2
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 13 sources